Document is current
Any future updates will be listed below
-
Authors
Liu, Fangyu
Mailhot, Olivier https://orcid.org/0000-0002-7533-4561
Glenn, Isabella S.
Vigneron, Seth F.
Bassim, Violla
Xu, Xinyu
Fonseca-Valencia, Karla https://orcid.org/0000-0002-7495-6262
Smith, Matthew S.
Radchenko, Dmytro S. https://orcid.org/0000-0001-5444-7754
Fraser, James S. https://orcid.org/0000-0002-5080-2859
Moroz, Yurii S. https://orcid.org/0000-0001-6073-002X
Irwin, John J. https://orcid.org/0000-0002-1195-6417
Shoichet, Brian K. https://orcid.org/0000-0002-6098-7367
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM122481, GM145238, GM71896)
Damon Runyon Postdoctoral Fellowship
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 13 November 2024
First Online: 3 January 2025
Competing interests
: B.K.S. is a founder of Epiodyne, Inc.; BlueDolphin, LLC; and Deep Apple Therapeutics, Inc., and serves on the SAB of Schrodinger LLC and of Vilya Therapeutics, and on the SRB of Genentech. J.J.I. cofounded Deep Apple Therapeutics, Inc., and BlueDolphin, LLC. J.S.F. is a consultant for, has equity in and receives research support from Relay Therapeutics. The other authors declare no competing interests.
